FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547436397> ?p ?o ?g. }

• W2547436397 endingPage "979" @default.
• W2547436397 startingPage "972" @default.
• W2547436397 abstract "BACKGROUND: Long-term opioid therapy for chronic pain may lead to analgesic tolerance, especially when administered intrathecally, thus preventing adequate pain relief. Discovering drug targets to treat opioid tolerance using a mechanism-based approach targeting opioid-induced neuroinflammation provides new therapeutic opportunities. In this study, we provide translational evidence that CXCL12/CXCR4 signaling contributes to the pathogenesis of opioid tolerance. METHODS: The CXCL12 levels in the cerebrospinal fluid of opioid-tolerant patients were compared with those of opioid-naive subjects. For further investigation, a rodent translational study was designed using 2 clinically relevant opioid delivery paradigms: daily intraperitoneal morphine injections and continuous intrathecal morphine infusion. We measured rats’ tail flick responses and calculated the percentage of maximum possible effects (%MPE) to demonstrate opioid acute antinociception and the development of analgesic tolerance. The effects of exogenous CXCL12, CXCL12 neutralizing antibody, and receptor antagonist AMD3100 were investigated by intrathecal administration. Data were presented as mean ± SEM. RESULTS: CXCL12 was significantly upregulated in the cerebrospinal fluid of opioid-tolerant patients for 892 ± 34 pg/mL (n = 27) versus 755 ± 33 pg/mL (n = 10) in naive control subjects ( P = .03). Furthermore, after 2 and 5 days of intrathecal morphine infusion, rat lumbar spinal cord dorsal horn CXCL12 messenger RNA levels were significantly upregulated by 3.2 ± 0.7 ( P = .016) and 3.4 ± 0.3 ( P = .003) fold, respectively. Results from the daily intraperitoneal morphine injection experiments revealed that administering an intrathecal infusion of CXCL12 for 24 hours before the first morphine injection did not decrease antinociception efficacy on day 1 but accelerated tolerance after day 2 (%MPE 49.5% vs 88.1%, P = .0003). In the intrathecal morphine coinfusion experiments, CXCL12 accelerated tolerance development (%MPE 9.4% vs 43.4% on day 1, P < .0001), whereas coadministration with CXCL12 neutralizing antibody attenuated tolerance (72.5% vs 43.4% on day 1, P < .0001; 47.6% vs 17.5% on day 2, P < .0001). Coadministration of receptor antagonist AMD 3100 can persistently preserve morphine analgesic effects throughout the study period (27.9% ± 4.1% vs 0.9% ± 1.6% on day 5, P = .03). CONCLUSIONS: The CXCL12/CXCR4 pathway contributes to the pathogenesis of opioid tolerance. Our study indicates that intervening with CXCL12/CXCR4 signaling has therapeutic potential for opioid tolerance." @default.
• W2547436397 created "2016-11-11" @default.
• W2547436397 creator A5001458811 @default.
• W2547436397 creator A5003296270 @default.
• W2547436397 creator A5018962578 @default.
• W2547436397 creator A5022540715 @default.
• W2547436397 creator A5029882037 @default.
• W2547436397 creator A5052254378 @default.
• W2547436397 creator A5077659189 @default.
• W2547436397 creator A5087042384 @default.
• W2547436397 date "2017-03-01" @default.
• W2547436397 modified "2023-10-16" @default.
• W2547436397 title "CXCL12/CXCR4 Signaling Contributes to the Pathogenesis of Opioid Tolerance: A Translational Study" @default.
• W2547436397 cites W149122356 @default.
• W2547436397 cites W190123231 @default.
• W2547436397 cites W1945174611 @default.
• W2547436397 cites W1969904009 @default.
• W2547436397 cites W1980850506 @default.
• W2547436397 cites W1988532660 @default.
• W2547436397 cites W1996183419 @default.
• W2547436397 cites W2005674933 @default.
• W2547436397 cites W2009784667 @default.
• W2547436397 cites W2018102225 @default.
• W2547436397 cites W2018762794 @default.
• W2547436397 cites W2023069769 @default.
• W2547436397 cites W2023582479 @default.
• W2547436397 cites W2035605437 @default.
• W2547436397 cites W2046296795 @default.
• W2547436397 cites W2052368774 @default.
• W2547436397 cites W2065950517 @default.
• W2547436397 cites W2073303656 @default.
• W2547436397 cites W2074800779 @default.
• W2547436397 cites W2081558146 @default.
• W2547436397 cites W2086236012 @default.
• W2547436397 cites W2086990722 @default.
• W2547436397 cites W2093031896 @default.
• W2547436397 cites W2094663125 @default.
• W2547436397 cites W2095728797 @default.
• W2547436397 cites W2098750842 @default.
• W2547436397 cites W2103076324 @default.
• W2547436397 cites W2108802610 @default.
• W2547436397 cites W2119337283 @default.
• W2547436397 cites W2128992312 @default.
• W2547436397 cites W2140441724 @default.
• W2547436397 cites W2161119197 @default.
• W2547436397 cites W2163318594 @default.
• W2547436397 cites W2170241188 @default.
• W2547436397 cites W2170756333 @default.
• W2547436397 cites W2171728059 @default.
• W2547436397 cites W3132839697 @default.
• W2547436397 cites W4292218105 @default.
• W2547436397 cites W59140152 @default.
• W2547436397 doi "https://doi.org/10.1213/ane.0000000000001480" @default.
• W2547436397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28212183" @default.
• W2547436397 hasPublicationYear "2017" @default.
• W2547436397 type Work @default.
• W2547436397 sameAs 2547436397 @default.
• W2547436397 citedByCount "13" @default.
• W2547436397 countsByYear W25474363972017 @default.
• W2547436397 countsByYear W25474363972018 @default.
• W2547436397 countsByYear W25474363972019 @default.
• W2547436397 countsByYear W25474363972020 @default.
• W2547436397 countsByYear W25474363972021 @default.
• W2547436397 countsByYear W25474363972022 @default.
• W2547436397 countsByYear W25474363972023 @default.
• W2547436397 crossrefType "journal-article" @default.
• W2547436397 hasAuthorship W2547436397A5001458811 @default.
• W2547436397 hasAuthorship W2547436397A5003296270 @default.
• W2547436397 hasAuthorship W2547436397A5018962578 @default.
• W2547436397 hasAuthorship W2547436397A5022540715 @default.
• W2547436397 hasAuthorship W2547436397A5029882037 @default.
• W2547436397 hasAuthorship W2547436397A5052254378 @default.
• W2547436397 hasAuthorship W2547436397A5077659189 @default.
• W2547436397 hasAuthorship W2547436397A5087042384 @default.
• W2547436397 hasConcept C118552586 @default.
• W2547436397 hasConcept C126322002 @default.
• W2547436397 hasConcept C15490471 @default.
• W2547436397 hasConcept C170493617 @default.
• W2547436397 hasConcept C2777389121 @default.
• W2547436397 hasConcept C2779651940 @default.
• W2547436397 hasConcept C2780775167 @default.
• W2547436397 hasConcept C2780820201 @default.
• W2547436397 hasConcept C2780942790 @default.
• W2547436397 hasConcept C2781063702 @default.
• W2547436397 hasConcept C42219234 @default.
• W2547436397 hasConcept C71924100 @default.
• W2547436397 hasConcept C98274493 @default.
• W2547436397 hasConceptScore W2547436397C118552586 @default.
• W2547436397 hasConceptScore W2547436397C126322002 @default.
• W2547436397 hasConceptScore W2547436397C15490471 @default.
• W2547436397 hasConceptScore W2547436397C170493617 @default.
• W2547436397 hasConceptScore W2547436397C2777389121 @default.
• W2547436397 hasConceptScore W2547436397C2779651940 @default.
• W2547436397 hasConceptScore W2547436397C2780775167 @default.
• W2547436397 hasConceptScore W2547436397C2780820201 @default.
• W2547436397 hasConceptScore W2547436397C2780942790 @default.
• W2547436397 hasConceptScore W2547436397C2781063702 @default.
• W2547436397 hasConceptScore W2547436397C42219234 @default.

• next